Biological Psychiatry. Editor: J. Mendlewicz (Brussels). Original Paper
Altered 5-HT2A and 5-HT4 Postsynaptic Receptors and Their Intracellular Signalling Systems IP3 and cAMP in Brains from Depressed Violent Suicide VictimsRosel P.a · Arranz B.b · Urretavizcaya M.c · Oros M.a · San L.b · Navarro M.A.a
aHormone Unit, Department of Biochemistry, CSU Bellvitge, bBenito Menni, Mental Health Care Institute, Hospital de Granollers, and cDepartment of Psychiatry, CSU Bellvitge, Barcelona, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Serotonin 5-HT2A and 5-HT4 binding parameters and their second messengers 1,4,5-inositol triphosphate (IP3) and cyclic adenosyl monophosphate (cAMP) were studied in the frontal cortex, hippocampus, caudate nucleus and amygdala of 19 control subjects and 19 antidepressant-free, violent suicide victims. A significantly higher number of 5-HT4 receptors and higher second messenger cAMP concentrations were found in the frontal cortex and caudate nucleus of the depressed suicide victims as compared with the control group. Furthermore, significantly increased 5-HT2A binding sites and IP3 concentrations were noted in the caudate nucleus of the suicide victims, together with a significantly reduced number of 5-HT2A binding sites, higher binding affinity and increased IP3 concentrations in the hippocampus. No significant alterations in 5-HT4 and cAMP or in 5-HT2A and IP3 concentrations were observed in the amygdala. The caudate nucleus of depressed suicide victims seems to be the brain region with the highest alteration of the serotonergic system, and hence with the most diagnostic sensitivity. Further studies on suicidality and depression should focus on the functionality of the caudate nucleus.
© 2004 S. Karger AG, Basel
- Mann JJ: Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999;21:99S–105S.
- Mendelson SD: The current status of the platelet 5-HT2A receptor in depression. J Affect Disord 2000;57:13–24.
- Van Heeringen C: Suicide, serotonin and the brain. Crisis 2001;22:66–70.
- Mann JJ, McBride PA, Brown RP, Linnoila M, Leon AC, DeMeo MD, Mieczkowski TA, Myers JE, Stanley M: Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch Gen Psychiatry 1992;49:442–446.
- Arranz B, Eriksson A, Mellerup E, Plenge P, Marcusson J: Brain 5-HT1A, 5-HT1D, 5-HT2 receptors in suicide victims. Biol Psychiatry 1994;35:457–463.
- Lowther S, De Parmentier F, Crompton MR, Katona CLE, Horton RW: Brain 5-HT2 receptors in suicide victims: Violence of death depression and effects of antidepressant treatment. Brain Res 1994;642:281–289.
- Pandey GN: Altered serotonin function in suicide. Evidence from platelet and neuroendocrine studies. Ann NY Acad Sci 1997;836:182–200.
- Rao ML, Hawellek B, Papassotiropoulos A, Deister A, Frahnert C: Upregulation of the platelet serotonin 2A receptor and low blood serotonin in suicidal psychiatric patients. Neuropsychobiology 1998;38:84–89.
- Dwivedi J, Pandey GN: Quantitation of 5-HT2A receptor mRNA in human postmortem brain using competitive RT-PCR. Neuroreport 1998;9:3761–3765.
- Turecki G, Brière R, Dewar K, Antonetti T, Lesage AD, Seguin M, Chawky N, Vanier C, Alda M, Joober R, Benkelfat C, Rouleau GA: Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 1999;156:1456–1458.
- Drevets WC: Neuroimaging studies of mood disorders. Biol Psychiatry 2000;48:813–829.
- Drevets WC: Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001;11:240–249.
- Leonard BE: Peripheral markers of depression. Curr Opin Psychiatry 2000;13:61–68.
- Leonard BE: Evidence for a biochemical lesion in depression. J Clin Psychiatry 2000;61:12–17.
- Berridge JM, Irvine RF: Inositol phosphates and cell signalling. Nature 1989;341:197–205.
- Berridge JM: Inositol trisphosphate and diacylglycerol as second messenger. Biochem J 1984;220:345–360.
Pandey SC, Davis JM, Schwertz DW, Pandey GN: Effect of antidepressant and neuroleptics on phosphoinositide metabolism in human platelets. J Phamacol Exp Ther 1991;256:1010–1018.
- Pandey GN, Dwivedi Y, Pandey SC, Conley RR, Roberts RC, Tamminga CA: Protein kinase C in postmortem brain of teenage suicide subjects. Neurosci Lett 1997;228:111–114.
- Warsh JJ, Li PP: Second messenger systems and mood disorders. Curr Opin Psychiatry 1996;9:23–29.
Mikuni M, Kusumi I, Kagaya A, Kuroda Y, Mori H, Takahashi K: Increased 5-HT2 receptor function as measured by serotonin stimulated phosphoinositide hydrolysis in platelets of depressed patients. Biol Psychiatry 1991;15:49–61.
- Karage F, Bovier P, Rudolph W, Gaillard JM: Platelet phosphoinositide signaling system: An overstimulated pathway in depression. Biol Psychiatry 1996;39:697–702.
- Pacheco MA, Jope RS: Phosphoinositide signalling in human brain. Prog Neurobiol 1996;50:255–273.
- Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE: Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 1997;154:1148–1150.
- Subhash MN, Jagadeesh S: Imipramine-induced changes in 5-HT2 receptor and inositoltrisphosphate levels in rat brain. Neurochem Res 1997;22:1095–1099.
- Lowther S, Katona CL, Crompton MR, Horton RW: Brain [3H]cAMP binding sites are unaltered in depressed suicides, but decreased by antidepressants. Brain Res 1997;758:223–228.
- Rosel P, Arranz B, Urretavizcaya M, Oros M, San L, Vallejo J, Navarro MA: Different distribution of the 5-HT reuptake complex and the postsynaptic 5-HT2A receptors in Brodmann areas and brain hemispheres. Psychiatry Res 2002;111:105–115.
- Rosel P, Arranz B, Oros M, Vallejo J, San L, Marcusson J, Navarro MA: Different regional distribution of the 5-HT reuptake complex, the 5-HT2A receptors and their second messenger IP3 in human brain. Neurosci Res Comm 1999;24:107–115.
- Rosel P, Arranz B, Vallejo J, Oros M, Crespo JM, Menchon JM, Navarro MA: Variations in [3H]imipramine and 5-HT2A but not [3H]paroxetine binding sites in suicide brains. Psychiatry Res 1998;82:161–170.
- Arranz B, Rosel P, San L, Sarró S, Navarro MA, Marcusson J: Characterization of the 5HT4 binding site in human brain. J Neural Transm 1998;105:575–586.
Markwell MA, Haas SM, Bieber LL, Tolbert NE: A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1987;87:202–225.
- Scatchard G: The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660–672.
- Gross-Isseroff R, Biegon A, Voet H, Weizman A: The suicide brain: A review of postmortem receptor/transporter binding studies. Neurosci Biobehav Rev 1998;22:653–661.
- Arranz B, Blennow K, Eriksson A, Mansson JE, Marcusson J: Serotonergic, noradrenergic and dopaminergic measures in suicide brains. Biol Psychiatry 1997;41:1000–1009.
Cheetham SC, Crompton MR, Katona CLE, Horton RW: Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res 1998;443:272–280.
- Shah PJ, Ebmeier KP, Glabus MF: Cortical gray matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 1998;172:527–532.
- Domenech T, Beleta J, Fernandez AG, Gristwood RW, Cruz Sanchez F, Tolosa E, Palacios JM: Identification and characterization of serotonin 5-HT4 receptor binding sites in human brain: Comparison with other mammalian species. Mol Brain Res 1994;21:176–180.
- Grossman CJ, Kilpatrick GJ, Bunce KT: Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain. Br J Pharmacol 1993;109:618–624.
- Eglen RM, Wong EHF, Dumuis A, Bockaert J: Central 5-HT4 receptors. Trends Pharmacol Sci 1995;16:391–397.
- Cowburn RF, Marcusson JO, Eriksson A, Wiehager B, O`Neill C: Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res 1994;633:297–304.
- Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT: G Protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: Effects of diagnosis, suicide and treatment at the time of death. J Neurochem 1999;73:1121–1126.
- Rehavi M, Jerusalemi Z, Aviv A, Laor N, Podliszawski KL, Shavat S, Weizman R: Interaction between antidepressant and phosphoinositide signal transduction system in human platelets. Biol Psychiatry 1993;33:40–44.
- Dwivedi Y, Janicak PG, Pandey GN: Elevated [3H]inositol 1,4,5-trisphosphate binding sites and expressed inositol 1,4,5-trisphosphate receptor protein level in platelets of depressed patients. Psychopharmacology 1998;138:47–54.
- Jakobs KA, Watanabe J, Bawer S: Interactions between the hormone-sensitive adenylate cyclase system and the phosphoinositide-metabolizing pathway in human platelets. J Cardiovasc Pharmacol 1986;8:61–64.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.